Background
Birt-Hogg-Dubé (BHD) syndrome is a familial disorder that predisposes patients to develop hair follicle hamartomas (84-90% penetrance), lung cysts (85% penetrance) and renal neoplasia (29-34% penetrance) [
1‐
5]. BHD patients are at risk to develop bilateral, multifocal renal tumors with a variety of histologies, mainly chromophobe (34%) and oncocytic hybrid (50%) tumors with features of both chromophobe renal cell carcinoma (RCC) and renal oncocytoma. Clear cell and papillary RCC as well as renal oncocytomas are also found in BHD patients at a low frequency [
6]. The BHD syndrome locus was mapped to chromosome 17p11.2 by linkage analysis in BHD families, and germline mutations in a novel gene
FLCN (alias
BHD), were identified and characterized [
5,
7‐
11]. Most BHD families carry germline mutations predicted to truncate the encoded protein, folliculin (FLCN), including insertion/deletion, nonsense, and splice-site mutations reported in several large BHD cohorts [
4,
5,
11]. Either somatic "second hit" mutations predicted to truncate the protein or loss of heterozygosity at the BHD syndrome locus was identified in 70% of renal tumors from BHD patients [
12] supporting a tumor suppressor function for
FLCN.
Two naturally-occurring animal models have been described that show phenotypes similar to BHD patients. The Nihon rat model develops renal carcinoma with clear cell histology by 6 months of age and harbors a cytosine insertion mutation in exon 3 of rat
Flcn [
13]. A canine model of BHD, which develops renal cystadenocarcinoma and nodular dermatofibrosis (RCND), carries a germline missense mutation (H255R) in canine
Flcn [
14]. Recently, we and others described a conditional
Flcn knockout mouse model in which
Flcn inactivation was targeted to mouse kidney using the Cre-lox site-specific recombination system. The affected mice displayed renal hyperplasia, formation of multiple cysts and renal dysfunction, suggesting important roles for
Flcn in regulation of renal cell proliferation [
15,
16]. No tumors formed before the animals died at 3 weeks of age due to renal failure, and therefore the mechanism by which
Flcn inactivation leads to kidney cancer could not be examined in this
in vivo model. However, recently we and others have reported that mice heterozygous for
Flcn develop renal cysts and tumors as they age beyond a year [
17‐
19], with demonstrated loss of the wild type copy of
Flcn (17). These
Flcn +/- mouse models more closely mimic BHD syndrome in the human, albeit with a long latency.
FLCN encodes a 64 kDa protein with no characteristic functional domains, which forms a complex with novel folliculin-interacting proteins 1 and 2 (FNIP1 and FNIP2), and 5'-AMP-activated protein kinase (AMPK), an important energy sensor in cells that negatively regulates mammalian target of rapamycin (mTOR) [
20,
21]. Phosphorylation of FLCN and FNIP1 was regulated by AMPK and mTOR activities suggesting a functional relationship with the AMPK-mTOR pathway. Interestingly, activation of mTOR downstream signaling molecules was seen in kidney-targeted
BHD conditional knockout mouse kidneys [
15,
16]. In addition, the renal tumors from BHD patients showed increased phosphorylation of mTOR [
15]. In contrast to these results, it was suggested that yeast homologs of
FLCN and
TSC1/2 may have opposing roles in amino acid homeostasis [
22]. The cysts and renal tumors derived from the
Flcn heterozygous mice described by Hartman et al. showed reduced phospho-S6R suggesting diminished mTOR activation [
18]. On the other hand Hasumi and coworkers found upregulation of both mTORC1 and mTORC2 pathways in kidney tumors from
Flcn
d/+
mice [
17]. Hudon et al. suggest that up or down regulation of mTOR by inactivation of
Flcn in a mouse model may be context-dependent [
19]. Thus it is possible that mTOR signaling is regulated differently by FLCN depending on cell types or experimental conditions.
A renal cancer cell line (UOK257) established from a BHD patient was recently developed and characterized [
23]. UOK257 cells harbor a cytosine insertion in a (poly)C tract, the frequently mutated "hot spot" within exon 11 of
FLCN (c.1285dupC), and have lost the wild-type copy of
FLCN. Cytogenetic analysis revealed that the cell line was nearly triploid displaying multiple unbalanced translocations and deletions of chromosomes. The MYC copy number was heterogeneous in UOK257 cells ranging from 3 to 5 copies. These cells formed tumors in immunodeficient mice (SCID/BEIG) exhibiting predominantly atypical clear epithelial cell type histology, as well as a variety of other histologic types including tubular papillary, and foci reminiscent of chromophobe RCC, all of which resemble the histologies within the tumor from which the cell line was derived [
23].
In the current study, in order to investigate the tumor suppressor function of FLCN we have introduced wild-type FLCN into UOK257 cells and compared their growth in vitro and in vivo. We found that wild-type FLCN suppressed tumor cell growth in vivo, confirming the tumor suppressor function of FLCN. In addition, we employed gene expression microarray analysis to identify novel downstream target genes of FLCN. Among the differentially expressed genes, we identified several critical genes involved in TGF-β signaling including TGFB2, INHBA, THBS1, GREM1 and SMAD3. Since deregulation of TGF-β signaling is important in tumorigenesis and tumor progression, we characterized the expression of these genes in FLCN-null and FLCN-expressing cultured cells as well as in renal tumors surgically removed from BHD patients. In addition, we examined the growth suppressive effect of activin A in the FLCN-null cell line and investigated receptor mediated TGF-β signaling in FLCN-null and FLCN-restored cell lines.
Discussion
UOK257 is the only renal cancer cell line available to date that has been established from a BHD patient's tumor tissue. This cell line is particularly valuable for study of the biological role of
FLCN inactivation in tumorigenesis because it harbors a
FLCN mutation predicted to produce only truncated mutant protein and induces the growth of tumors
in vivo with histology resembling the BHD-associated renal tumor from which it was derived [
23]. In this study, we have established and characterized UOK257 cell lines in which wild-type or mutant
FLCN was stably expressed. Although anchorage dependent cell growth
in vitro was not affected by wild-type
FLCN expression, cell growth
in vivo and anchorage-independent growth in soft agar were severely diminished by the expression of wild-type
FLCN. We have searched for downstream target genes regulated by
FLCN through gene expression microarray analysis and identified a number of genes that were differentially expressed in wild-type
FLCN (UOK257-2, -4, and -6) compared with mutant
FLCN and
FLCN-null (UOK257-H255R and -P) cells. We found three prominent groups of genes involved in cadherin signaling, TGF-β signaling, and angiogenesis. Notably, several key genes involved in TGF-β signaling, such as
TGFB2,
INHBA,
THBS1 and
SMAD3, were down-regulated in
FLCN-null and mutant
FLCN cells as well as in the BHD-associated renal tumors. Consistently,
GREM1, the antagonist of BMP that signals through SMADs was highly up-regulated in mutant
FLCN and
FLCN-null UOK257 cells although its expression was low in BHD-associated renal tumors.
We observed that the expression level of FLCN is important for tumor suppression, since the UOK257 cell lines (UOK257-4, -2 and -6) expressing high levels of FLCN did not develop tumors whereas the UOK257-3 cell line expressing a very low level of FLCN, did develop tumors with a low incidence (2 out of 10). It is likely that the FLCN expression level in UOK257-3 cells is marginal for tumor suppression, allowing tumor growth in some animals but suppressing tumor growth in others. In support of this idea, the expression levels of the downstream target genes in UOK257-3 cells were either similar to
FLCN-null and
FLCN mutant cells (UOK257-P and UOK257-H255R), or midway between the
FLCN-null-
FLCN mutant group and the
FLCN-restored group, which expressed high levels of FLCN (UOK257-2 and UOK257-6) (See additional file
1: Fig. S3).
UOK257-H255R cells expressed a low level of FLCN protein resulting in loss of tumor suppressor function and deregulation of TGF-β signaling, even though they expressed slightly more
FLCN mRNA than UOK257-4 cells (Fig.
1A and
1B). These data suggest that FLCN-H255R missense mutant protein found in the canine model of BHD syndrome is less stable than wild-type FLCN. Thus decreased stability of mutant FLCN is likely to contribute to the loss of FLCN tumor suppressor function.
It has been suggested that
Drosophila BHD (
dBHD) regulates germline stem cell (GSC) maintenance downstream or in parallel with Jak/Stat and dpp (BMP ortholog in
Drosophila) signaling [
24].
dBHD knockdown by siRNA suppressed overproliferation of GSC induced by hyperactivation of Jak/Stat or dpp signaling. Interestingly,
Jak1, encoding a kinase that transmits signals by phosphorylating Stats in cells, was identified by microarray analysis as a downregulated gene in the mutant
FLCN and
FLCN-null cells (Fig.
3A). We also identified several key genes in TGF-β/BMP signaling such as
TGFB2,
INHBA,
THBS1 and
SMAD3 (a regulatory SMAD) that were down-regulated in the mutant
FLCN and
FLCN-null cells. On the other hand,
GREM1, which encodes a protein that binds and inactivates BMP activity, was upregulated in the mutant and
FLCN-null cells. Thus the genetic interactions between
dBHD, and Jak/Stat and dpp (BMP) signaling may be partially explained by
FLCN deregulation of genes involved in these pathways.
The human TGF-β superfamily consists of 42 members including TGF-βs, activins, bone morphogenic proteins (BMPs), and growth and differentiating factors (GDFs) [
25,
26]. TGF-βs are multi-functional cytokines that modulate cell proliferation, apoptosis, differentiation, adhesion and migration. TGF-β shows a biphasic effect on tumor cell growth [
27]. It inhibits tumor cell growth in the early phase of tumorigenesis but promotes cell growth when cells escape the anti-proliferative effect of TGF-β in the late phase of tumorigenesis. Interestingly, TGF-β2 induced anchorage independent growth of UOK257 cells (Fig.
6C), suggesting that UOK257 cells are refractory to the growth suppressive effect of TGF-β. The possibility exists that reduced expression of TGF-β2 in
FLCN-null cells contributed to cell growth in the early phase of tumorigenesis.
Disruption of TGF-β signaling has been reported in many cancers. TGF-β type II receptor is often mutated in gastro-intestinal cancers [
28‐
30]. Mutations in SMAD2 or SMAD4 occur frequently in pancreatic and colorectal carcinomas [
31‐
33]. Although mutations in SMAD3 have not been reported, 3 out of 8 (37.5%) gastric tumors in one report showed low to undetectable levels of SMAD3 expression and restoration of SMAD3 suppressed tumorigenicity of gastric cancer cells [
34]. Low levels of SMAD3 expression in the BHD tumors may contribute to the ability of these renal tumor cells to escape the growth suppressive effect of TGF-β.
Activins are homo- or heterodimeric proteins consisting of two β subunits (βA and βB), while inhibins are heterodimers of α and β subunits (inhibin-A [αβA] and inhibin-B [αβB]) [
35]. INHBA is one of the β subunits (βA) that comprise activin A (βAβA), activin AB (βAβB) and inhibin A (αβA). Activin A regulates kidney organogenesis, tubular regeneration and renal fibrosis [reviewed in [
36]]. Activins also induce apoptosis, and inhibit cell proliferation and tumor growth in numerous types of cells. In contrast to TGF-β2, activin A inhibited growth of UOK257 cells in soft-agar (Fig.
6D), suggesting that activin signaling is intact in UOK257 cells. Thus reduced expression of
INHBA, β subunit of activin A, in UOK257 cells and BHD tumors, may be permissive for tumor cell growth. It would be interesting to examine whether activin A treatment can suppress BHD tumor growth
in vivo.
Thrombospondin-1 (THBS1) is one of the five members of a family of thrombospondins that mediate the interaction of normal and cancer cells with the extracellular matrix and surrounding tissue. THBS1 suppresses tumor growth by activating TGF-β and by inhibiting angiogenesis. THBS1 exerts direct effects on endothelial cell migration and survival through interaction with CD36. It also reduces availability of VEGF by inhibiting MMP9, therefore releasing VEGF from the extracellular matrix. There are several reports suggesting that reduced expression of THBS1 or hypermethylation of
THBS1 is associated with poor prognosis of cancer patients and higher tumor grade [
37‐
40]. Accordingly THBS1 regulation may be an important part of the tumor suppressor function of
FLCN.
We examined whether TGF-β signaling is dysregulated by the inactivation of the FLCN gene. TGF-β or BMP4 induced SMAD3 or SMAD1/5/8 phosphorylation was not affected by FLCN inactivation suggesting receptor mediated SMAD phosphorylation is not altered by FLCN. However, several genes whose expressions are regulated by TGF-β were dysregulated by the inactivation of FLCN. The basal and maximal induced levels of the downstream target genes (TGFB2, INHBA and SMAD7) regulated by TGF-β were reduced in cells with FLCN inactivation. These data suggest that FLCN may regulate TGF-β signaling through a non-SMAD mediated mechanism. As a result of such regulation, the level of TGF-β ligands, such as TGF-β2 and activin A, could be highly induced in cells expressing FLCN by a positive feedback control.
A possible function of FLCN in energy sensing and metabolism has been suggested by its interaction with AMPK through FNIP1/2 and by the observation that FLCN phosphorylation is affected by mTOR signaling (20-21). Here we demonstrated that an AMPK activator, AICAR, and an AMPK inhibitor, Compound C, as well as an mTOR inhibitor, rapamycin, affected the expression of the same key molecules involved in TGF-β signaling, which appear to be regulated by FLCN. Thus FLCN could be a key molecule connecting energy-sensing signals to growth suppressive TGF-β signaling.
Methods
Establishment of cell lines, cell culture, and cell growth
Wild-type or mutant (H255R) FLCN cDNA was transduced into UOK257 cells using the ViraPower Lentiviral expression system (Invitrogen) following the manufacturer's protocols. Stable clones were selected using Blasticidin S (1.5 μg/ml). Cells were maintained in DMEM medium supplemented with 10% fetal bovine serum (FBS) and penicillin/streptomycin. To evaluate growth rate in culture, cells (2 × 103) were plated in each well of five 96 well plates, cultured, and cell numbers were measured at day 1, 2, 3, 5 and 7 using the CyQuant Cell Proliferation Assay Kit (Molecular Probes). Adenoviral vectors (pAd/CMV/V5-DEST) expressing wild-type and mutant (c.1285dupC) FLCN were generated using the ViraPower Adenoviral Gateway system (Invitrogen) following the manufacturer's protocol. A retroviral shRNA vector targeting FLCN was generated by inserting double stranded oligonucleotides (forward sequence, 5'-GATCCCCGGTGTTTGAGGCAGAGCAGTTCAAGAGACTGCTCTGCCTCAAACACCTTTTTA-3' and reverse sequence, 5'-GCTTAAAAAGGTGTTTGAGGCAGAGCAGTCTCTTGAACTGCTCTGCCTCAAACACCGGG-3') into HindIII and BglII sites of pSuper-Retro vector (Oligoengine) following the manufacturer's instruction. UOK257-2 cells were infected with the FLCN shRNA vectors and selected against puromycin (7.5 ug/ml).
UOK257 cells (5 × 103) were suspended in 1.5 ml of 0.3% agar in DMEM containing 10% FBS and were overlayed on 1.5 ml of pre-solidified 0.5% agar in the same medium. Cells were cultured in a CO2 incubator for 3-4 weeks. Colonies were stained for 1 hour with 0.02% crystal violet solution dissolved in 10% neutral formalin. Colony number was counted under a dissection microscope after washing with PBS three times.
Tumor growth in nude mice
Cells (1 × 106) suspended with basement membrane matrix (BD Biosciences) were injected subcutaneously into the flanks of athymic nude mice. Tumor growth was measured once a week and mouse health was monitored daily. Mice bearing tumors larger than 2 cm, or showing severe health problems, were sacrificed and examined. Otherwise tumor growth was monitored for up to one year after injection. Tumors were fixed in 10% buffered formalin solution for histological examination and flash frozen in liquid nitrogen for protein and RNA extraction. Animal care procedures followed NCI-Frederick Animal Care and Use Committee guidelines.
Immunoblotting
Cells were harvested and lysed in RIPA buffer (50 mM Tris-Cl, pH 8.0 with 150 mM NaCl, 1.0% NP-40 and 0.5% sodium deoxycholate) or 1× SDS sample buffer (Biorad). Cell lysates were resolved by 4-20% SDS PAGE and blotted onto PVDF membrane. The following antibodies were used in this study: anti-FLCN mouse monoclonal [
20], anti-β-actin (Sigma), anti-SMAD2/3 (Santa Cruz, sc-6032), and anti-pSMAD2/3 (Santa Cruz, sc-11769) antibodies. Immunoblots were processed by the ECL Detection System (Pierce) according to the manufacturer's protocols.
Immunohistochemistry
Paraffin tissue sections were deparaffinized, rehydrated in graded alcohol and boiled in Tris-EDTA buffer pH 8.0 for 20 min at 90°C for antigen retrieval. After blocking, sections were probed with primary antibodies overnight and then incubated with HRP-polymer conjugated secondary antibodies. Diaminobenzidine hydrochloride (DAB) was used as a substrate for peroxidase. Sections were then briefly counterstained with hematoxylin and permanently mounted for observation.
ELISA
Cells (2 × 105) were cultured on 6 well plates for 3 days and culture media was collected for assay. TGF-β2, and activin A levels in the media were quantified by Human TGF-β2 DuoSet (R&D systems) and activin A DuoSet (R&D systems), respectively, following the manufacturer's instruction.
RNA isolation, microarray analysis and pathway analysis
Total RNAs were isolated from the UOK257 cell lines using Trizol reagent (Invitrogen) and further purified using RNeasy mini kit (QIAGEN) according to the manufacturer's protocols. Probes, which were generated using these RNAs, were hybridized to the Human Genome U133 Plus 2.0 arrays (Affymetrix) and processed according to recommended protocols. The CEL files were processed using the Partek Genomic Suite 6.2 (Partek Inc.). Data were transformed using a log normalization process and the differentially expressed genes were identified by Student's t-test and Mann-Whitney U-test. The genes that were differentially expressed in mutant FLCN cell lines (UOK257-P and -H255R) and wild-type FLCN cell lines (UOK257-2, -4 and -6) were used for further analysis.
Quantitative real-time reverse transcription-PCR (RT-PCR)
To confirm the microarray results, quantitative real-time reverse transcription PCR (RT-PCR) was performed. RNAs were digested with DNase I for 30 min at 37°C followed by heat denaturation at 70°C for 20 min to remove genomic DNA contamination. Total RNAs (2.5 μg) were primed with 100 ng random primers and reverse-transcribed by Superscript II reverse transcriptase (Invitrogen) at 42°C for 1 hr. The identical reactions were performed without reverse transcriptase to generate negative controls. PCR primers were generated using Primer 3 software [
41] or Primer Express 3.0 (Applied Biosystems). Quantitative RT-PCR was performed with Power SYBR-Green or Taqman Gene Expression Master Mix (Applied Biosystems) using a 7300 Real-Time PCR system (Applied Biosystems) following the manufacturer's protocols. All reactions were run in triplicate using
β-actin,
GAPDH or
cyclophilin A genes as internal controls. The relative level of a particular gene expression was evaluated according to the function of 2
-ddCt, where ddCt is dCt
(treatment) - dCt
(control), dCt is Ct
(target gene) - Ct
(GAPDH or actin) and Ct is the cycle at which the threshold is crossed. The gene-specific primer pairs for the PCR reactions are as follows:
FLCN forward 5'-TTCACGCCATTCCTACACCAGA-3' and reverse 5'-GCCCACAGGTTGTCATCACTTG-3',
GREM1 forward 5'-GCAAAACCCAGCCGCTTAA-3' and reverse 5'-TGATGGTGCGACTGTTGCA-3',
TGFB2 forward 5'-CGAGAGGAGCGACGAAGAGT-3' and reverse 5'-AGGGCGGCATGTCTATTTTG-3',
THBS1 forward 5'-CCAGATCAGGCAGACACAGA-3' and reverse 5'-AGTTGTCCCGTTCATTGAGG-3',
INHBA forward 5'-TGGAGTGTGATGGCAAGGTCA-3' and reverse 5'-GCATGATAGCCAGAGGGAGCA-3',
SMAD3 forward 5'-GACGAGGTCTGCGTGAATCC-3' and reverse 5'-GTGGCGTGGCACCAACA-3', and
GAPDH forward 5'-TTCCACCCATGGCAAATTCC-3' and reverse 5'-CGCCCCACTTGATTTTGGAG-3'.
SMAD7 forward 5'-CCAACTGCAGACTGTCCAGA-3' and reverse 5'-CAGGCTCCAGAAGAAGTTGG-3'. PCR product quality was monitored using post-PCR dissociation curve analysis.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
SBH designed the experiments. SBH, VAV, HBO, JS, DTN and MB performed the experimental work. MB generated critical cell lines for the work. MJM performed histopathologic analysis. SBH wrote the manuscript. WML and LSS contributed to the design of the experiments, review of the data, scientific discussions and manuscript editing. All authors read and approved the final manuscript.